Sotagliflozin: a combined SGLT1/SGLT2 inhibitor to treat diabetes

References

• Zhao FQ, Keating AF. Functional properties and genomics of glucose transporters. Curr Genom. 2007;8:113–128.
   PubMed Web of Science ®Google Scholar
• Chen J, Williams S, Ho S, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther. 2010; 1:57–92.
   PubMedGoogle Scholar
• Song P, Onishi A, Koepsell H, et al. Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. Expert Opin Ther Targets. 2016;20:1109–1125.
   PubMed Web of Science ®Google Scholar
• Von Mering J. Ueber kunstlichen diabetes. Centralbl Med Wiss. 1886;xxii:531.
   Google Scholar
• Ehrenkranz JRL, Lewis NG, Kahn CG, et al. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21:31–38.
   PubMed Web of Science ®Google Scholar
• Wright EMI. Glucose-galactose malabsorption. Am J Physiol. 1998;275:G879–G882.
   PubMed Web of Science ®Google Scholar
• Gorboulev V, Schurmann A, Vallon V, et al. Na(#)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes. 2012;61:187–196.
   PubMed Web of Science ®Google Scholar
• Powell DR, Smith M, Greer J, et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther. 2013;345:250–259.
   PubMed Web of Science ®Google Scholar
• Wilding JPF. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metab Clin Exp. 2014;63:1228–1237.
   PubMed Web of Science ®Google Scholar
• Powell DR, Smith MG, Doree DD, et al. LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2. Pharm Res Perspec. 2015;3:1–11.
   Web of Science ®Google Scholar
• Rieg T, Masuda T, Gerasimova M, et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol. 2014;306:F188–F193.
   PubMed Web of Science ®Google Scholar
• Goodwin NC, Mabon R, Harrison BA, et al. Novel L-Xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. J Med Chem. 2009;52:6201–6204.
   PubMed Web of Science ®Google Scholar
• Powell DR, DaCosta CM, Smith M, et al. Effect of LX4211 on glucose homeostasis and body composition in preclinical models. J Pharmacol Exp Ther. 2014;350:232–242.
   PubMed Web of Science ®Google Scholar
• Powell DR, DaCosta CM, Gay J, et al. Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol Metab. 2013;304:E117–E130.
   PubMed Web of Science ®Google Scholar
• Lapuerta P, Zambrowicz B, Strumph P, et al. Development of sotagliflozin, a dual sodiumdependent glucose transporter 1/2 inhibitor. Diab Vasc Disease Res. 2015;12:101–110.
   PubMed Web of Science ®Google Scholar
• Powell DR, Doree D, Jeter-Jones S, et al. Sotagliflozin improves glycemic control in NOD mice with type 1 diabetes. Diabetes Metab Syndr Obes. 2015;8:121–127.
   PubMed Web of Science ®Google Scholar
• Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized,placebo-controlled trial. Clin Pharmacol Ther. 2015;92:158–169.
   Web of Science ®Google Scholar
• Zambrowicz B, Lapuerta P, Strumph P, et al. LX4211 reduces postprandial glucose in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion. Clin Ther. 2015;37:71–82.
   PubMed Web of Science ®Google Scholar
• Zambrowicz B, Ding Z-M, Ogbaa I, et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. Clin Ther. 2013;35:273–285.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Cefalu WT, Lapuerta P, et al. Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy. Diabetes Care. 2015;38:431–436.
   PubMed Web of Science ®Google Scholar
• Rendell MS, Jovanovic L. Targeting postprandial hyperglycemia. Metabolism. 2006;55:1263–1281.
   PubMed Web of Science ®Google Scholar
• Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care. 2015;38:1181–1188.
   PubMed Web of Science ®Google Scholar
• Buse JB, Garg SK, Rosenstock J, et al. Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 study. Diabetes Care. 2018 [Epub ahead of print]
   Web of Science ®Google Scholar
• Danne T, Cariou B, Banks P, et al. HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European in Tandem2 study. Diabetes Care. 2018;41(9):1981-1990.
   Web of Science ®Google Scholar
• Garg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med. 2017;377:2337–2348.
   PubMed Web of Science ®Google Scholar
• Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38::1687–93.
   Web of Science ®Google Scholar
• Erondu N, Desai M, Ways K, et al. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38:1680–1686.
   PubMed Web of Science ®Google Scholar
• Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(11):864–876.
   PubMed Web of Science ®Google Scholar
• Jensen DM, Korsholm L, Ovesen P, et al. Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. Diabetes Care. 2009;32:1046–1048.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes. 13. Management of diabetes in pregnancy. Diabetes Care. 2014;40:S114–S119.
   Google Scholar
• Parker JA, Conway DL. Diabetic ketoacidosis in pregnancy. Obstet Gynecol Clin North Am. 2007;34:533–543.
   PubMed Web of Science ®Google Scholar
• Sibai BM, Viteri OA. Diabetic ketoacidosis in pregnancy. Obstet Gynecol. 2014;123:167–178.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-frandsen K, et al; LEADER steering committee on behalf of the LEADER trial investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
   PubMed Web of Science ®Google Scholar
• Bilezikian JP, Watts NB, Usiskin K, et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab. 2016;101:44–51.
   PubMed Web of Science ®Google Scholar
• Tucker ME FDA warns about amputation risk with canagliflozin. http://www.medscape.com/viewarticle/863485 cited 2016 Jun 26
   Google Scholar